Toinv

That is one perceptive analysis - Hepa leaps to worldwide BP status with the opportunistic acquisition of Resverlogix - a pioneer of epigenetics - the future standard of care. 

With all the confusion in the lower 48 - the Trump admin & preoccupation with numerous other domestic issues, FDA leadership turnover, North Korean and Iranian sabre rattling, China's tentative support of US sanctions against NK, coupled with the inability to get the FDA and BP on board, HEPA's strategy is brilliant - 42% is damn close to control.

I have often wondered how Dr Wong views the Hepa connection and if Hepa's involvement somehow stems from his Chinese or family connections. I recently saw a pie chart with his % of ownership but couldn't find it for this post - I thought it was 3-5%. Shawn Lu, the new director and CFO of Hepalink's US subsidiary also has an interest in Quest Pharma Tech Inc - TSX Venture and is eligible for option awards. 

Many recent posters have alluded to the LOI as being in addition to the Hepa transaction - is that a fact or conjecture?

I don't know whose move it is but look out - we could see checkmate before FA.

I hope not. 

JMO

Chicagoest